Education
About Us
Working with TipRanks
Follow Us
Medpace Holdings (MEDP)
NASDAQ:MEDP
MEDP Stock Chart & Stats
$569.70
$7.21(2.08%)
At close: 4:00 PM EST
$569.70
$7.21(2.08%)
Day’s Range― - ―
52-Week Range$250.05 - $626.26
Previous CloseN/A
Volume64.09K
Average Volume (3M)251.05K
Market Cap
$16.05B
Enterprise Value$14.68B
Total Cash (Recent Filing)$285.35M
Total Debt (Recent Filing)$143.97M
Price to Earnings (P/E)39.8
Beta1.14
Next Earnings
Feb 16, 2026EPS Estimate
4.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.86
Shares Outstanding28,168,222
10 Day Avg. Volume231,720
30 Day Avg. Volume251,052
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)12.46
Price to Sales (P/S)4.88
P/FCF Ratio17.97
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue6.22
Enterprise Value/Gross Profit20.00
Enterprise Value/Ebitda28.18
Forecast
1Y Price Target
$557.50Price Target Upside-2.14% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)14.8
Revenue Forecast (FY)$2.51B
Bulls Say, Bears Say
Bulls Say
Client Base GrowthMEDP is a global CRO with a client-base that skews heavily toward SMid-sized biotechs, which should be a faster-growing end-market over the longer-term.
Financial PerformanceThe company signed a record $790M net new business, representing a book-to-bill of 1.20x, up meaningfully from previous quarters.
Revenue GrowthRevenue from metabolic trials up over 80% year-over-year and nearly 33% sequentially, and revenue from its top 5 customers up nearly 50% year-over-year and roughly 45% sequentially.
Bears Say
Margin PressureAn upcoming re-acceleration in hiring will likely create some near/medium-term pressure on margins.
Stock OvervaluationThe stock is now trading at 41.0x our current 2026 EPS estimate, significantly above its peer group average of 15.5x.
Valuation ConcernsSustaining MEDP's current 28x valuation against a tepid biotech funding backdrop leaves little cushion for additional potential macro volatility.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $250.05 and its highest was $626.25 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $16.05B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Feb 16, 2026 which is in 53 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Oct 22, 2025. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.535 by $0.325.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Overvalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 4.19.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 28,168,222 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $3.86 in its last earnings report, beating expectations of $3.535. Following the earnings report the stock price went up 9.121%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$557.50 (-2.14% Downside)
$557.50 (-2.14% Downside)
Blogger Sentiment
Bullish
MEDP Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 51.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $223.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.02%
12-Months-Change
Fundamentals
Return on Equity
73.70%
Trailing 12-Months
Asset Growth
-15.88%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
MEDP Company Deck
MEDP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and business growth, with significant net new business awards and a record net book-to-bill ratio. Despite these positive aspects, there were challenges related to a higher effective tax rate, lower interest income, and cancellations. Overall, the call demonstrates a strong performance with some areas for improvement.View all MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$557.50
▼(-2.14% Downside)
Technical Analysis
Ownership Overview
19.54% Insiders
21.61% Mutual Funds
28.64% Other Institutional Investors
8.13% Public Companies and
Individual Investors